# Effects of Thickening Agents Used in Dysphagia on the In Vitro Dissolution of Gliclazide

**Authors:** Ayman Allahham, Seerat Fatima, Ieva Stupans, Thilini Thrimawithana, Vivek B. Nooney

PMC · DOI: 10.3390/pharmacy14020044 · 2026-03-04

## TL;DR

This study examines how thickening agents used for dysphagia affect the dissolution of gliclazide tablets in laboratory conditions.

## Contribution

The study reveals that Gloup® Forte significantly delays gliclazide dissolution compared to other media.

## Key findings

- Gliclazide dissolution was significantly delayed in Gloup® Forte across all media.
- Mixing gliclazide with Gloup® Forte reduced the dissolution rate constant in both crushed and whole tablets.

## Abstract

Dysphagia is common among older adults and frequently necessitates the use of thickening agents to facilitate safe swallowing of medicines, which may in turn alter their bioavailability. This study investigated the impact of two commercially available lubricants—Gloup® Forte and extremely thick water—on the in vitro dissolution behaviour of immediate-release gliclazide tablets. Dissolution studies were conducted using crushed and whole tablets in different media consisting of reverse osmosis water, phosphate buffer (pH 6.8), and 0.1 N HCl at 37 °C. Dissolution profiles were compared using similarity factor (f2) analysis and modelled using established kinetic equations. Gliclazide dissolution was significantly delayed in the presence of Gloup® Forte across all media for both crushed and whole tablets, with f2 values below 50, indicating dissimilar profiles. Dissolution kinetics confirmed that mixing the formulated gliclazide with Gloup® Forte delayed the release and reduced the dissolution rate constant for drug from both crushed and whole gliclazide tablets in media studied.

## Linked entities

- **Chemicals:** gliclazide (PubChem CID 3475)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** neurological disorders (MESH:D009461), Alzheimer's disease (MESH:D000544), Parkinson's disease (MESH:D010300), DM (MESH:D003920), traumatic brain injury (MESH:D000070642), Dysphagia (MESH:D003680), stroke (MESH:D020521), metabolic disorder (MESH:D008659), injury to (MESH:D014947), aspiration pneumonia (MESH:D011015)
- **Chemicals:** HCL (MESH:D006851), Carrageenan (MESH:D002351), sodium phosphate tribasic dodecahydrate (MESH:C018279), sucrose (MESH:D013395), metformin (MESH:D008687), sugar (MESH:D000073893), xanthan (MESH:C002563), tara gum (MESH:C038612), water (MESH:D014867), Sodium Starch Glycolate (MESH:C048390), starch (MESH:D013213), dextrose (MESH:D005947), citric acid (MESH:D019343), paracetamol (MESH:D000082), phosphate (MESH:D010710), EQ (-), Gliclazide (MESH:D005907), potassium sorbate (MESH:D013011), sulfonylurea (MESH:D013453), maltodextrin (MESH:C008315)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13010598/full.md

---
Source: https://tomesphere.com/paper/PMC13010598